Take the next step
Be Part of the Future of Health Research
Whether you're a researcher or participant, Alethios makes health research effortless and impactful.
Early-stage innovators in human health are often asked to prove too much, too early, with too little support. We believe credible human research should be accessible earlier—and to more kinds of teams. The Alethios Early-Stage Program provides reduced-cost access to our research platform for teams running real human studies
At Alethios, we work with teams running human health studies every day. Some are established companies with mature products and clear clinical roadmaps. Others are researchers, founders, or small teams just getting started — often with something genuinely new, ambitious, and hard to categorize.
We constantly see both sides of the system, and as a result, we see where it breaks.
Traditional funding, clinical infrastructure, and research models tend to favor incumbents — teams with existing capital, networks, or institutional backing. There are countless ideas, interventions, and approaches that could have been transformative but never made it past the starting line. Not because they lacked merit, but because they were too early, too unconventional, or too difficult to fund within existing systems.
We don't think early evidence generation should be the reason promising work never gets a chance.
We believe credible human research should be accessible earlier—and to more kinds of teams.
Not every idea needs a massive randomized controlled trial on day one. But many ideas do benefit from well-designed pilots, observational studies, or early interventional work that generates real signal and informs next steps.
This belief is central to how we approach research at Alethios: not as a single leap, but as a ladder. Early studies lay the groundwork for what comes next, helping teams uncover meaningful signals that can be scaled and invested in over time.
The Alethios Early-Stage Program is our way of lowering the barrier to that first rung.
The Early-Stage Program provides discounted access to the Alethios research platform — including free access to the Study Planner and discounted use of the full Study Operator environment. Pricing is tailored to each team and may include reduced licensing and support fees or a pay-what-you-can model.
The expectation is simple: the research should matter — informing real product, clinical, or scientific decisions.
Note: Discounts apply to Alethios platform fees only; third-party costs are not included.
We built this program for teams who may be structurally disadvantaged by traditional research models — particularly early-stage companies (Pre-seed through Series A, typically with under $5M raised), academic groups, and innovators in consumer health, CPG, biotech, diagnostics, and digital health preparing to launch a human study within the next 90 days.
This program is specifically for those early in their journey — when access, not ambition, is the limiting factor.
We give special consideration to teams working in chronically underfunded or under-researched areas of health, addressing populations historically excluded from clinical research, or facing barriers where early human evidence generation has been prohibitively expensive, logistically complex, or otherwise out of reach.
We’re proud to share that Kioga Bio is the first company to graduate from the Alethios Early Stage Program.
Kioga Bio joined the program as an early-stage ingredient company in 2024 looking to generate meaningful human evidence to support their scientific approach. Through Alethios, the team designed and executed two structured clinical studies aligned with their early evidence goals.
The results helped inform downstream product, partnership and fundraising decisions and gave the team a stronger foundation for future research.
As part of the program, we sat down with the Kioga Bio team to talk about why early evidence mattered to them, how they approached study design as a small team, and what they learned from running their first Alethios-powered study.
→ Read the Kioga Bio interview and case study
Kioga Bio has since graduated from the program and continues to use Alethios as part of their research infrastructure.
We keep the cohort intentionally small so we can be thoughtful about who we support and why.
If you’re an entrepreneur, researcher, or innovator in human health—and you’re ready to run a real study—we’d love to hear from you.
Apply to the Alethios Early stage Program
.png)
Whether you're a researcher or participant, Alethios makes health research effortless and impactful.
.svg)